N
Nicholas P. Restifo
Researcher at National Institutes of Health
Publications - 413
Citations - 87375
Nicholas P. Restifo is an academic researcher from National Institutes of Health. The author has contributed to research in topics: T cell & Cytotoxic T cell. The author has an hindex of 140, co-authored 408 publications receiving 77995 citations. Previous affiliations of Nicholas P. Restifo include Government of the United States of America & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Cancer immunotherapy: moving beyond current vaccines.
TL;DR: Results in cancer vaccine trials are considered and alternate strategies that mediate cancer regression in preclinical and clinical models are highlighted.
Journal ArticleDOI
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley,John R. Wunderlich,Paul F. Robbins,James Chih-Hsin Yang,Patrick Hwu,Douglas J. Schwartzentruber,Suzanne L. Topalian,Richard M. Sherry,Nicholas P. Restifo,Amy M. Hubicki,Michael R. Robinson,Mark Raffeld,Paul H. Duray,Claudia A. Seipp,Linda Rogers-Freezer,Kathleen E. Morton,Sharon Mavroukakis,Donald E. White,Steven A. Rosenberg +18 more
TL;DR: The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
Journal ArticleDOI
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan,Mark E. Dudley,John R. Wunderlich,Michael S. Hughes,James Chih-Hsin Yang,Richard M. Sherry,Richard E. Royal,Suzanne L. Topalian,Udai S. Kammula,Nicholas P. Restifo,Zhili Zheng,Azam V. Nahvi,Christiaan R. de Vries,Linda Rogers-Freezer,Sharon Mavroukakis,Steven A. Rosenberg +15 more
TL;DR: The ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor is reported.
Journal ArticleDOI
Adoptive cell transfer as personalized immunotherapy for human cancer.
TL;DR: The ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.
Journal ArticleDOI
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Steven A. Rosenberg,James Chih-Hsin Yang,Douglas J. Schwartzentruber,Patrick Hwu,Francesco M. Marincola,Suzanne L. Topalian,Nicholas P. Restifo,Mark E. Dudley,Susan L. Schwarz,Paul J. Spiess,John R. Wunderlich,Maria R. Parkhurst,Yutaka Kawakami,Claudia A. Seipp,Jan Einhorn,Donald E. White +15 more
TL;DR: A synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma and, on the basis of immunologic assays, 91% of patients could be successfully immunized with this peptide.